NCT01457989View on ClinicalTrials.gov

Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304

CompletedOBSERVATIONAL

Enrollment

1

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Epilepsy, Partial

Interventions

DRUG

retigabine/ezogabine

dose range up to 1200 mg/day

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01457989 - Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304 | Biotech Hunter | Biotech Hunter